These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37028510)

  • 41. Long-term prophylaxis for hereditary angioedema: Initial experiences with garadacimab and lanadelumab.
    Wong JCY; Chiang V; Lam DLY; Lee E; Lam K; Au EYL; Li PH
    J Allergy Clin Immunol Glob; 2023 Nov; 2(4):100166. PubMed ID: 38024849
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Using an extended treatment regimen of lanadelumab in the prophylaxis of hereditary angioedema: a single-centre experience.
    Abuzakouk M; Ghorab O; Al-Hameli H; Salvo F; Grandon D; Maurer M
    World Allergy Organ J; 2022 Jul; 15(7):100664. PubMed ID: 35891672
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
    Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT
    Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of lanadelumab in hereditary angioedema: a case series of 12 patients in Canada.
    Iaboni A; Kanani A; Lacuesta G; Song C; Kan M; Betschel SD
    Allergy Asthma Clin Immunol; 2021 Jul; 17(1):78. PubMed ID: 34301329
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effectiveness of lanadelumab for preventing hereditary angioedema attacks: Subgroup analyses from the HELP study.
    Johnston DT; Busse PJ; Riedl MA; Maurer M; Anderson J; Nurse C; Inhaber N; Yu M; Banerji A;
    Clin Exp Allergy; 2021 Oct; 51(10):1391-1395. PubMed ID: 34166549
    [No Abstract]   [Full Text] [Related]  

  • 46. Therapeutic monoclonal antibodies with a focus on hereditary angioedema.
    Zuraw BL; Maurer M; Sexton DJ; Cicardi M
    Allergol Int; 2023 Jan; 72(1):54-62. PubMed ID: 35787344
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and Safety of Donidalorsen for Hereditary Angioedema.
    Riedl MA; Tachdjian R; Lumry WR; Craig T; Karakaya G; Gelincik A; Stobiecki M; Jacobs JS; Gokmen NM; Reshef A; Gompels MM; Manning ME; Bordone L; Newman KB; Treadwell S; Wang S; Yarlas A; Cohn DM;
    N Engl J Med; 2024 Jul; 391(1):21-31. PubMed ID: 38819395
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety, effectiveness, and impact on quality of life of self-administration with plasma-derived nanofiltered C1 inhibitor (Berinert®) in patients with hereditary angioedema: the SABHA study.
    Zanichelli A; Azin GM; Cristina F; Vacchini R; Caballero T
    Orphanet J Rare Dis; 2018 Apr; 13(1):51. PubMed ID: 29631595
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A focus on the use of subcutaneous C1-inhibitor for treatment of hereditary angioedema.
    Villavicencio MF; Craig T
    Expert Rev Clin Immunol; 2020 May; 16(5):451-455. PubMed ID: 32237900
    [TBL] [Abstract][Full Text] [Related]  

  • 50. How Angioedema Quality of Life Questionnaire Can Help Physicians in Treating C1-Inhibitor Deficiency Patients?
    Balla Z; Ignácz B; Varga L; Kőhalmi KV; Farkas H
    Clin Rev Allergy Immunol; 2021 Aug; 61(1):50-59. PubMed ID: 33660212
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Psychosocial burden of type 1 and 2 hereditary angioedema: a single-center Canadian cohort study.
    Hews-Girard J; Goodyear MD
    Allergy Asthma Clin Immunol; 2021 Jun; 17(1):61. PubMed ID: 34187550
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Psychometric Field Study of Hereditary Angioedema Quality of Life Questionnaire for Adults: HAE-QoL.
    Prior N; Remor E; Pérez-Fernández E; Caminoa M; Gómez-Traseira C; Gayá F; Aabom A; Aberer W; Betschel S; Boccon-Gibod I; Bouillet L; Bygum A; Csuka D; Farkas H; Gomide M; Grumach A; Leibovich I; Malbran A; Moldovan D; Mihaly E; Obtulowicz K; Perpén C; Peveling-Oberhag A; Porebski G; Chavannes CR; Reshef A; Staubach P; Wiednig M; Caballero T
    J Allergy Clin Immunol Pract; 2016; 4(3):464-473.e4. PubMed ID: 26969268
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Quality of life in patients with hereditary angioedema receiving therapy for routine prevention of attacks.
    Lumry WR; Miller DP; Newcomer S; Fitts D; Dayno J
    Allergy Asthma Proc; 2014; 35(5):371-6. PubMed ID: 25295804
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The impact of biological interventions for ulcerative colitis on health-related quality of life.
    LeBlanc K; Mosli MH; Parker CE; MacDonald JK
    Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD008655. PubMed ID: 26393522
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [EFFICACY, PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF INTRAVENOUS C1 INHIBITOR FOR LONG-TERM PROPHYLAXIS AND TREATMENT OF BREAKTHROUGH ATTACKS IN JAPANESE SUBJECTS WITH HEREDITARY ANGIOEDEMA: A PHASE 3 OPEN-LABEL STUDY].
    Fukunaga A; Morita E; Miyagi T; Eto K; Shimizu A; Kagami S; Yamamoto H; Vardi M; Tang Y; Wang Y; Hide M
    Arerugi; 2020; 69(3):192-203. PubMed ID: 32435020
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Letter in reply: network meta-analysis for indirect comparison of lanadelumab and for the treatment of hereditary angioedema.
    Watt M; Malmenas M; Haeussler K
    J Comp Eff Res; 2024 May; 13(5):e240041. PubMed ID: 38606574
    [No Abstract]   [Full Text] [Related]  

  • 57. Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine-preventive medications in the phase 3b FOCUS study.
    Spierings ELH; Ning X; Ramirez Campos V; Cohen JM; Barash S; Buse DC
    Headache; 2021 Oct; 61(9):1376-1386. PubMed ID: 34374086
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Health-related quality of life with hereditary angioedema following prophylaxis with subcutaneous C1-inhibitor with recombinant hyaluronidase.
    Weller K; Maurer M; Fridman M; Supina D; Schranz J; Magerl M
    Allergy Asthma Proc; 2017 Mar; 38(2):143-151. PubMed ID: 28093999
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The humanistic burden of hereditary angioedema: Impact on health-related quality of life, productivity, and depression.
    Lumry WR; Castaldo AJ; Vernon MK; Blaustein MB; Wilson DA; Horn PT
    Allergy Asthma Proc; 2010; 31(5):407-14. PubMed ID: 20929608
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Patient-reported burden of hereditary angioedema: findings from a patient survey in the United States.
    Banerji A; Davis KH; Brown TM; Hollis K; Hunter SM; Long J; Jain G; Devercelli G
    Ann Allergy Asthma Immunol; 2020 Jun; 124(6):600-607. PubMed ID: 32169514
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.